Researchers from Shenyang Pharmaceutical University and affiliated organizations have reported the identification of a selective cyclin-dependent kinase 9 (CDK9) inhibitor, CLZX-205, being developed for the treatment of colorectal cancer.
Researchers from the Chinese Academy of Sciences and affiliated organizations discovered a new ubiquitin-specific protease 7 (USP7) inhibitor, YCH-2823, being developed as a potential anticancer agent.
Researchers from Haisco Pharmaceutical Group Co. Ltd. presented the discovery and preclinical characterization of a brain-penetrating BRAF paradox breaker, HSK-42360, being developed for the treatment of BRAF-driven cancers. HSK-42360 proved to be a potent BRAF V600E inhibitor (IC50=5 nM) with selectivity over wild-type BRAF.
Werner syndrome helicase (WRN), which plays important roles in DNA repair and maintenance of genome integrity, has been recently identified as therapeutic target for microsatellite instability (MSI)-H tumors, which have deficiencies in DNA damage repair.
Researchers from Dong-A Socio Holdings Co. Ltd. presented a first-in-class Src homology 2 domain-containing phosphatase 1 (SHP1) allosteric inhibitor, SB-8091, being developed as an anticancer agent.
In tumors with amino acid deprivation, eIF-2α kinase GCN2 is activated and triggers a signaling response to promote cell survival and proliferation. This is important in high metabolically active hematological cancers, such as acute myeloid leukemia (AML).
AR-V7 is the most clinically relevant androgen receptor (AR) splice variant associated with endocrine resistance and poor prognosis in patients with prostate cancer.
Using its artificial intelligence/machine learning platform, Aurigen, Auron Therapeutics Inc. has identified histone acetyltransferase KAT2A/B as a driver of tumor cell plasticity and designed new small-molecule degraders of KAT2A/B.
Despite GTPase KRAS being the most common mutated oncogene in human cancers, there is still an unmet medical need for treating KRAS G12C-mutated cancers.
Zinc transporter ZIP6, also known as LIV-1, is a transmembrane protein that is an interesting target for antibody-drug conjugate (ADC) therapy because of its higher expression in tumors and almost no expression in normal tissues.
RSS
